{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T14:53:38Z","timestamp":1777560818979,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Mycology Case Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.mmcr.2025.100736","type":"journal-article","created":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T05:26:33Z","timestamp":1758605193000},"page":"100736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Isavuconazole: Need for therapeutic drug monitoring and CYP polymorphism testing"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1578-9932","authenticated-orcid":false,"given":"Rajeev","family":"Soman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2934-7089","authenticated-orcid":false,"given":"Sanraksha","family":"Mayya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rahul","family":"Doshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inderdeep","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushrut","family":"Ganpule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mmcr.2025.100736_bib1","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad704","article-title":"A systematic review of the therapeutic outcome of mucormycosis","volume":"11","author":"Sigera","year":"2023","journal-title":"Open Forum Infect. Dis."},{"issue":"12","key":"10.1016\/j.mmcr.2025.100736_bib2","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical Mycology in cooperation with the mycoses study group education and research consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.mmcr.2025.100736_bib3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","article-title":"Pharmacokinetics and Pharmacodynamics of posaconazole","volume":"80","author":"Chen","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.mmcr.2025.100736_bib4","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1086\/428780","article-title":"Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases","volume":"191","author":"Kontoyiannis","year":"2005","journal-title":"J. Infect. Dis."},{"issue":"7","key":"10.1016\/j.mmcr.2025.100736_bib5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.mmcr.2025.100736_bib6","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01034-17","article-title":"Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi","volume":"61","author":"Desai","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.mmcr.2025.100736_bib7","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1093\/jac\/dkae139","article-title":"Isavuconazole as prophylaxis and therapy for invasive fungal diseases: a real-life observational study","volume":"79","author":"Erg\u00fcn","year":"2024","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.mmcr.2025.100736_bib8","article-title":"P173 PK PD rationale and efficacy of isavuconazole treatment after failure of amphotericin B and posaconazole for COVID-19 associated cranial Mucormycosis","volume":"60","author":"Soman","year":"2022","journal-title":"Med. Mycol."},{"key":"10.1016\/j.mmcr.2025.100736_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijid.2022.04.009","article-title":"Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series","volume":"120","author":"Soman","year":"2022","journal-title":"Int. J. Infect. Dis."},{"issue":"6","key":"10.1016\/j.mmcr.2025.100736_bib10","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1093\/jac\/dkaf128","article-title":"Isavuconazole therapeutic drug monitoring and association with adverse events","volume":"80","author":"Huang","year":"2025","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Medical Mycology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211753925000454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211753925000454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T13:08:29Z","timestamp":1769173709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211753925000454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":10,"alternative-id":["S2211753925000454"],"URL":"https:\/\/doi.org\/10.1016\/j.mmcr.2025.100736","relation":{},"ISSN":["2211-7539"],"issn-type":[{"value":"2211-7539","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isavuconazole: Need for therapeutic drug monitoring and CYP polymorphism testing","name":"articletitle","label":"Article Title"},{"value":"Medical Mycology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mmcr.2025.100736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of International Society for Human and Animal Mycology.","name":"copyright","label":"Copyright"}],"article-number":"100736"}}